Influenza: XOFLUZA well-tolerated in children with the flu in Phase III study
by Press Release from Outbreak News Today on (#4JG7P)
Genentech announced this week that the Phase III MINISTONE-2 study met its primary endpoint, demonstrating that XOFLUZAa (baloxavir marboxil) was well-tolerated in children with the flu. The study also showed that XOFLUZA is comparable to oseltamivir - a proven effective treatment for children with the flu - at reducing the duration of flu symptoms, including ["]
The post Influenza: XOFLUZA well-tolerated in children with the flu in Phase III study appeared first on Outbreak News Today.